title: B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants.
abstract: OBJECTIVE
  Haemodynamically significant patent ductus arteriosus (hsPDA) is frequently observed in premature infants. This study was conducted to explore whether the blood BNP can be a valuable biomarker to assess the necessity of treatment for hsPDA in premature infants.
  
  
  METHODS
  Serial measurements of the blood BNP were performed during the first 5 days of life in premature infants with hsPDA (Group I) and those without hsPDA (Group N). The definition of the hsPDA was the PDA requiring treatment, such as indomethacin administration and/or surgical ligation.
  
  
  RESULTS
  Forty-six subjects were enrolled. Compared with Group N, Group I showed significantly higher level of blood BNP at postnatal 24-96 h and demonstrated the peak value at postnatal 24-48 h. With the ROC curve using the data at postnatal 24-48 h in Group I, we deduced the predictive value of 250 pg/mL of blood BNP for indomethacin treatment. Similarly, with the ROC curve using the maximal value of blood BNP within the first 5 days of life, the predictive value of 2000 pg/mL for surgical ligation was deduced.
  
  
  CONCLUSIONS
  Blood BNP during early postnatal period can be a useful biomarker to assess the necessity of treatment for hsPDA in premature infants.
authors.affiliation: Department of Pediatrics, Kansai Medical University, Osaka, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Mine
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ohashi
authors.forename: Shoji
authors.initials: S
authors.lastname: Tsuji
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Nakashima
authors.forename: Masato
authors.initials: M
authors.lastname: Hirabayashi
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kaneko
mesh_terms: D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004374:Ductus Arteriosus, Patent / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D008026:Ligation / Q000379:methods; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011237:Predictive Value of Tests; D012372:ROC Curve; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D020097:Natriuretic Peptide, Brain; D007213:Indomethacin